<DOC>
	<DOCNO>NCT01279694</DOCNO>
	<brief_summary>Phase I/II trial Carfilzomib plus melphalan prednisone elderly untreated patient multiple myeloma . Nine : University Hospital Nantes , University Hospital Nancy , University Hospital Lille , University Hospital Tours , department Hospital La Roche Sur Yon , University Hospital Reims , University Hospital Clermont-Ferrand , University Hospital Toulouse , University Hospital Dijon Newly diagnose symptomatic Multiple Myeloma &gt; 65 year . Treatment comprise initial phase consist nine 6-week cycle Carfilzomib Days 1 , 2 , 8 , 9 , 22 , 23 , 29 , 30 ( carfilzomib administer 20 mg/m2 Days 1 2 first cycle 20 , 27 , 36 45 mg/m2 thereafter ) follow 12 day rest period ( 42-day cycle ) , combination oral Melphalan 9 mg/m² oral prednisone 60mg/m² , day 1 4 . Phase I : Identification Maximum Tolerated Dose ( MTD ) Carfilzomib administer dose 20mg/m² dos first cohort 6 patient . If dose-limiting toxicity ( DLTs ) occur few 2 patient , next cohort 6 patient ( cohort 2 ) receive dose 20/27 mg/m² 20 mg/m² dose administer Day 1 2 Cycle 1 27 mg/m² subsequent dos . If DLTs occur few 2 patient cohort 2 , third cohort 6 patient receive dose 20/36 mg/m² 20 mg/m² dose administer Day 1 2 Cycle 1 36 mg/m² subsequent dos . If DLTs occur few 3 patient cohort 3 fourth cohort 6 patient receive dose 20/45 mg/m² 20 mg/m² dose administer Day 1 2 Cycle 1 45 mg/m² subsequent dos . If time cycle 1 dose cohort , ≥ 2 subject experience drug-related DLT , MTD exceed , additional enrollment within cohort cease , dose escalation stop . The MTD define dose level DLT observe ≥ 33 % ( i.e . ≥ 2 6 ) subject cohort . The following defined DLTs : - Any hematologic toxicity grade 4 intensity prevent administration 2 8 carfilzomib dos first treatment cycle except ) grade 4 thrombocytopenia without bleed last ≤ 7 day b ) grade 4 neutropenia last ≤ 7 day - Grade ≥ 3 febrile neutropenia - Grade ≥ 3 gastrointestinal toxicity ( except grade ≥ 3 nausea/ vomit patient receive adequate antiemetic prophylaxis ) - Any grade ≥ 3 nonhematologic toxicity consider related CMP principal investigator . - Grade ≥ 3 peripheral neuropathy persist 3 week discontinuation study drug . Adverse event ( AEs ) grade accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE , version 4.0 ) . MTD determination base occurrence DLTs first induction treatment cycle . Phase II : Expanded Cohort . After identification MTD , plan dose cohort expand include total 20 patient treat MTD phase II part study . A full treatment course phase I : nine 6-week cycle CMP . PRIMARY ENDPOINT Phase I : MTD combination Phase II : Overall response rate [ ( ORR ) , consist complete response ( CR ) , good partial response ( VGPR ) , partial response ( PR ) SECONDARY ENDPOINTS Safety tolerability CMP Clinical benefit response [ ( CBR = ORR + minimal response ( MR ) ] , Progression-free survival ( PFS ) , Duration response Overall survival ( OS ) . Safety data analysis conduct subject receive least one dose study treatment . Analyses consist data summary report AEs . The number percentage subject experience one AEs summarize dose , relationship study drug , severity . AEs cod use MedDRA terminology . Disease Response Analyses : Overall response rate ( ORR = CR + VGPR + PR ) treatment measure use International Myeloma Working Group ( IMWG ) criterion . Clinical benefit response ( CBR = ORR + MR ) determine use minimal response ( least 6 week duration ) define European Group Blood Marrow Transplant ( EBMT ) . The distribution subject response category make overall dose cohort . Time-to-event endpoint evaluate use Kaplan-Meier method plot provide . Analysis time-to-event outcome perform overall sample .</brief_summary>
	<brief_title>Trial Carfilzomib Plus Melphalan Prednisone Elderly Untreated Patients With Multiple Myeloma ( CARMYSAP )</brief_title>
	<detailed_description>The primary objective phase I/II study identify appropriate dose Carfilzomib combination standard MP treatment regimen ( phase I ) evaluate efficacy Carfilzomib plus MP ( CMP ) term overall response rate [ ( ORR ) , consist complete response ( CR ) , good partial response ( VGPR ) , partial response ( PR ) ( phase II ) ] . Phase I/II single arm open label</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Karnofsky performance status ( KPS ) least 60 % Life expectancy 3 month . Must understand voluntarily sign informed consent form Age &gt; 65 year time sign consent Previously untreated , symptomatic multiple myeloma define 2 criterion : ○ MM diagnostic criterion ( 3 require ) : · Monoclonal plasma cell bone marrow ≥10 % and/or presence biopsyproven plasmacytoma· Monoclonal protein present serum and/or urine· Myelomarelated organ dysfunction ( least 1 follow ) [ C ] Calcium elevation blood ( serum calcium &gt; 10.5 mg/L upper limit normal ) [ R ] Renal insufficiency ( serum creatinine &gt; 2 mg/dL ) [ A ] Anemia ( hemoglobin &lt; 10 g/dL 2 g &lt; normal ) [ B ] Lytic bone lesion osteoporosisAND measurable disease protein electrophoresis analysis define one following : · IgG multiple myeloma : Serum monoclonal paraprotein ( M protein ) level SPEP ³ 0.5 g/dL urine Mprotein level ³ 200 mg/24 hours· IgA multiple myeloma : Serum Mprotein level ³ 0.5 mg/dL urine Mprotein level ³ 200 mg/24 hours· IgM multiple myeloma ( IgM Mprotein plus lytic bone disease document skeletal survey plain film ) : Serum Mprotein level ≥ 1.0 g/dL urine Mprotein level ≥ 200 mg/24 hours· IgD multiple myeloma : Serum Mprotein level ³ 0.05 g/dL urine Mprotein level ³ 200 mg/24 hour Light chain multiple myeloma : Patients serum free light chain disease involve light chain measure ≥ 10 mg/dL ECOG performance status 0 , 1 , 2 Able adhere study visit schedule protocol requirement Affiliation number National Health Care System Patients ineligible meet follow criterion : 1 Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid [ i.e. , less equal equivalent dexamethasone 40 mg/day 4 day ; short course steroid treatment must give within 28 day ( 4 week ) consent ] ) . Any serious medical condition place patient unacceptable risk participates study . Female childbearing potential Any follow laboratory abnormality : · Absolute neutrophil count ( ANC ) &lt; 1,000 cells/mL ( 1.0 × 109/L ) · Platelet count &lt; 50,000 cells/mL ( 50 × 109/L ) patient &lt; 50 % bone marrow nucleate cell plasma cell ; platelet count &lt; 30,000 cells/mL patient ³ 50 % bone marrow nucleate cell plasma cell · Serum SGPT/ALT &gt; 3.0 × upper limit normal ( ULN ) ; Bilirubin &gt; 2 × ULN [ ALT specific liver ] · Creatinine clearance ≤ 30 mL/min ( CockcroftGault calculation ) 5 Prior history malignancy , multiple myeloma , unless subject free disease ³ 3 year . Exceptions include follow : Basal cell carcinoma skin Squamous cell carcinoma skin Carcinoma situ cervix Carcinoma situ breast6 Incidental histological finding prostate cancer ( TNM stage T1a T1b ) Peripheral neuropathy &gt; grade 2 severity . Known HIV positivity active infectious hepatitis , type A , B , C. Myocardial infarction within 3 month enrollment , unstable angina within 2 month New York Heart Association class III IV heart failure . Oral IV fluid hydration contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>newly-diagnosed multiple myeloma .</keyword>
</DOC>